Navigation Links
Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
Date:11/9/2007

ng innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza(R), a DNA demethylating agent. For additional information about Pharmion, please visit the company's website at http://www.pharmion.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This release contains forward-looking statements, including summary statements relating to the interim or preliminary results of clinical trials involving Amrubicin. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause the final results to differ significantly from the results summarized by such statements. Preliminary results may not be confirmed upon final analysis of the detailed results of a trial and additional information relating to the safety, efficacy or tolerability of Amrubicin may be discovered upon further analysis of clinical trial data and upon review and analysis of additional clinical trial data from this or other clinical trials. Additional risks and uncertainties relating to Pharmion and its business can be found in the "Risk Factors" section of Pharmion's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2007, its Annual Report on Form 10-K for the year ended December 31, 2006 and in Pharmion's other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made, and Pharmion undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise. Pharmion also disclaims any duty to comment upon or correct information that may be contained in reports published by the inves
'/>"/>

SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
4. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
5. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
6. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
7. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
8. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
9. Feeling Anxious or Distracted? New Research Shows a Cup of Tea Could Help
10. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
11. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 18, 2013  Actavis, Inc. (NYSE: ACT ) ... the U.S. Securities and Exchange Commission (SEC) a registration statement ... Warner Chilcott plc (NASDAQ: WCRX ), ... Warner Chilcott (the "Form S-4"). As previously ... have entered into a definitive agreement pursuant to which ...
(Date:6/18/2013)... CHAPEL HILL, N.C. , June 18, 2013 /PRNewswire/ ... and more difficult for Medical Education groups at large ... practitioners on the safe and effective use of their ... within the pharma industry, it is crucial that these ... of reaching healthcare professionals. To address the ...
(Date:6/18/2013)... SAN LEANDRO, Calif. , June 18, 2013 /PRNewswire/ ... world.  According to the American Association of Ophthalmology, aging ... cataracts, a clouding of the eye,s natural lens. 22 ... by 2020, as Baby Boomers continue to age, that ... moving, high tech world of iPhones, iPads, smart-phones and ...
Breaking Medicine Technology:Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 2Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 3Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 4Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 5Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 6Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 7Though Vital to Educating Doctors on New Products, Pharma "Med Ed" Groups Working Under Huge Internal & External Constraints 2New Vision Hope For Millions Undergoing Cataract Surgery 2New Vision Hope For Millions Undergoing Cataract Surgery 3
... 14 The Fifth Annual Orthopedic Design & Technology (ODT) Conference & Exhibition ... Center, Fort Wayne, Ind. , ... global event brings together orthopedic finished good manufacturers, suppliers and surgeons for networking, general ... , , ...
... 14 MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) has retained ... England to manage its planned Phase IIb clinical trial in the ... treatment of primary multiple sclerosis-related fatigue (PMSF). , ... In an earlier Phase IIa study, MCT-125 was tested ...
Cached Medicine Technology:Fifth Annual Orthopedic Design & Technology Conference & Exhibition Set for September 22-23 2Fifth Annual Orthopedic Design & Technology Conference & Exhibition Set for September 22-23 3MultiCell Hires Clinical Research Organization to Manage MCT-125 Phase IIb Clinical Trial 2MultiCell Hires Clinical Research Organization to Manage MCT-125 Phase IIb Clinical Trial 3MultiCell Hires Clinical Research Organization to Manage MCT-125 Phase IIb Clinical Trial 4
(Date:6/19/2013)... DiscountFurnaceFilter.com, the number one solution for homeowner’s ... Compressor Saver kit at an exceptional price. The 5-2-1 Compressor ... air conditioning unit during start up, saving wear and tear ... unit burn out. , The 5-2-1 Compressor Saver ... uses less power to start and drastically reduces the rush ...
(Date:6/19/2013)... 19, 2013 Kansas City will host its first ... Street Day . A section of Main Street in the midtown ... afternoon of the event. The Main Street Corridor Development ... will help Kansas City join the ranks of dozens of cities ... tool to foster community vibrancy and active lifestyles. , “Ciclovia is ...
(Date:6/19/2013)... June 19, 2013 In 2011, the ... EUR 710 million. Generic drugs form the largest sector, ... value. The pharmaceutical industry is a significant contributor to ... the country’s GDP. Approximately 50% of the total domestic ... pharmaceutical industry. Hemofarm, Galenika and Zdravlje Actavis are key ...
(Date:6/19/2013)... Elsevier, a world-leading provider of scientific, technical ... the publication of the National Osteoporosis Guideline Group ... osteoporosis in postmenopausal women and older men in ... 2009 in Maturitas , the original guidelines ... timely with an additional focus on the management ...
(Date:6/19/2013)... Next Thursday, June 27, 2013, ... organization, and Muzzy Lane Software , a ... the Games for Health community to their interactive ... toward students in grades 4-7 and designed to ... positive choices. The game is part of a ...
Breaking Medicine News(10 mins):Health News:Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia 2Health News:Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia 3Health News:Serbian Pharmaceutical Market Scrutinized by CUBE in Topical Report Now Available at MarketPublishers.com 2Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 2Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 3Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 4Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 5
... Fla. and COLUMBUS, Ohio, May 20 Axium ... specialty pharmacy providers, and Definitive Homecare Solutions, the ... of CPR+ as its specialty pharmacy management software ... continued growth, we needed a software platform to ...
... The Technical Board of,Appeal of the European Patent Office ... two competitors against an earlier decision to maintain the,European ... http://www.newscom.com/cgi-bin/prnh/20090520/347917-a ) , ... Introduced in 1999, the VisionBlue product is protected ...
... managed by a specialty pharmacy program were more compliant ... hospitalized for their disease than those who were not ... study completed by HealthCore, Inc. , HealthCore researcher Jingbo ... of Pharmacoeconomic and Outcomes Research 14th Annual International Meeting ...
... RECORDING OF DAVID COOK,S ,IDOL, PERFORMANCE WILL BE SOLD ... Sale of Live Version of ,Permanent, Will Be Donated ... Exactly one year after winning the seventh season ... popular television series in America on Wednesday night to ...
... To commemorate the 80th anniversary of The Children,s ... in Midtown Detroit, a Power of Possibilities Breakfast is ... Book Cadillac.(Logo: http://www.newscom.com/cgi-bin/prnh/20090423/CCWCLOGO ) ... on the ideologies of founder Senator James Couzens. ...
... Ill., May 20 Viant, Inc., a leader in ... they have signed an agreement with Tempe, AZ-based HMA, ... the state of Arizona. Viant customers utilizing the Beech ... access to HMA, Inc.,s Arizona provider networks, which include, ...
Cached Medicine News:Health News:Axium Healthcare Picks CPR+ as Its Specialty Pharmacy Management Software 2Health News:Axium Healthcare Picks CPR+ as Its Specialty Pharmacy Management Software 3Health News:Appeal Proceedings on European VisionBlue Patent Stayed; Patent Remains in Force 2Health News:Appeal Proceedings on European VisionBlue Patent Stayed; Patent Remains in Force 3Health News:MS patients more compliant with medications when managed by specialty pharmacy 2Health News:David Cook to Perform 'Permanent' on the American Idol Season Finale Tonight 2Health News:80th Anniversary Power of Possibilities Breakfast Honors the Children's Center of Wayne County 2Health News:Viant Expands Relationship With HMA for Improved Healthcare Access in AZ 2
... is a small, quiet, high-speed centrifuge. It ... system which results in nearly vibration- free ... both top speed and full breaking in ... changed with a simple push-on/ pull-off; transforming ...
The StatSpin Express 3 provides faster turnaround time and greater productivity for your laboratory....
... Used to establish temporary internal drainage ... following renal transplant. Non-radiopaque ink bands serve ... physician can anticipate where the coil(s) will ... sterile in peel-open packages. Intended for one-time ...
Used for drainage and retrograde pyelogram in pediatric patients. A stiffening stylet is included to aid in catheter placement. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: